Semaglutide Purification via Halogenated Solvent and RP-HPLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying semaglutide and liraglutide are not efficient, leading to a need for improved processes that can enhance the purification of these peptides.
Innovation Solution
A process involving the dissolution of crude semaglutide or liraglutide in a halogenated solvent, followed by two sequential RP-HPLC purifications, and a third RP-HPLC purification using a mobile phase containing a sodium salt, water, and acetonitrile to achieve salt-exchanged peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional RP-HPLC purification methods are used, then purification can be achieved, but the process is inefficient and complex
Solution Approach 1:
The patent changes the mobile phase composition parameters by introducing halogenated solvents (chlorinated or fluorinated) and specific buffer systems with controlled pH levels. This parameter modification optimizes the separation efficiency and purification speed, resolving the contradiction between productivity and complexity by making the process more efficient with standardized parameters
Solution Approach 2:
The purification process is divided into distinct sequential steps: dissolution in halogenated solvent, first RP-HPLC purification, second RP-HPLC purification, and salt exchange. This segmentation allows each step to be optimized independently, improving overall efficiency while maintaining clear process boundaries that reduce operational complexity
2Manufacturing precision
If multiple purification steps are performed, then purity increases, but the process becomes more complex and time-consuming
Solution Approach 1:
The patent employs parameter changes by using halogenated solvents and optimized buffer systems with specific pH values (e.g., pH 7.4 with citrate buffer) to enhance the separation efficiency of each purification step. This allows achieving high purity with fewer and more effective steps, reducing total process time while maintaining manufacturing precision
Solution Approach 2:
The patent introduces intermediary substances including halogenated solvents as dissolution media and specific buffer systems (citrate buffer, Tris buffer) as mobile phase components. These intermediaries facilitate efficient separation and purification, enabling high purity to be achieved through optimized intermediate steps rather than numerous sequential operations
3Quantity of substance
If traditional solvents are used, then dissolution can be achieved, but solubility and decarboxylation conditions are suboptimal
Solution Approach 1:
The patent changes the solvent parameter by using halogenated solvents (chlorinated or fluorinated compounds) instead of traditional aqueous solvents. This parameter change optimizes both the solubility of the peptide and the decarboxylation conditions, improving ease of manufacture while increasing the quantity of dissolved substance
Solution Approach 2:
The patent introduces halogenated solvents as intermediary dissolution media that simultaneously provide optimal solubility and facilitate decarboxylation. These intermediary substances create favorable chemical conditions for both dissolution and subsequent purification steps, resolving the contradiction between solubility and ease of manufacture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process results in higher purity and improved solubility of semaglutide and liraglutide, with better decarboxylation conditions and simplified operations compared to existing methods.
Implementation Method 1
dissolving crude semaglutide or liraglutide in a halogenated solvent
Implementation Method 2
subjecting the solution to a RP-HPLC purification system
Implementation Method 3
a third RP-HPLC purification using a mobile phase containing a sodium salt, water, and acetonitrile to achieve salt-exchanged peptides
Data Source
AI summary
The present invention provides improved processes for purifying semaglutide or liraglutide. Semaglutide or liraglutide is purified via two sequential RP-HPLC purifications followed by a salt-exchange step, where a pH is kept constant in the first and second purification steps. In particular, the processes utilize a halogenated solvent in a sample preparation step, which provides better solubility and an environment suitable for decarboxylation for crude semaglutide or liraglutide prior to a RP-HPLC purification.